Stockscreener 앱 받기
62.58
1.35%
-0.855
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Should you avoid Cytokinetics Incorporated stock right now2025 Risk Factors & Stepwise Trade Signal Guides - baoquankhu1.vn
Profit Recap: Is TCBX in accumulation or distribution phaseWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten) - PR Newswire
SG Americas Securities LLC Purchases 43,349 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With 41% Upside Potential - DirectorsTalk Interviews
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
FDA approves seven NMEs in December - biocentury.com
Jefferies raises Cytokinetics stock price target to $90 on ACACIA study - Investing.com Canada
How Cytokinetics Incorporated stock trades before earnings2025 Volume Leaders & Momentum Based Trading Ideas - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for long term wealth building2025 Institutional Moves & High Accuracy Trade Alerts - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for hedge fundsQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru
Is Cytokinetics Incorporated stock a good choice for value investorsWeekly Investment Report & Step-by-Step Swing Trade Plans - ulpravda.ru
Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Can Cytokinetics Incorporated stock deliver consistent earnings growthPortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru
What makes Cytokinetics Incorporated stock attractive to growth fundsIPO Watch & AI Based Trade Execution Alerts - ulpravda.ru
Risk Analysis: Can Cytokinetics Incorporated stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Can Cytokinetics Incorporated stock maintain growth trajectoryInsider Selling & Daily Profit Focused Screening - ulpravda.ru
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Press Telegram - FinancialContent
How Aficamten REMS Disclosure Probe Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
HC Wainwright & Co. maintains Cytokinetics (CYTK) buy recommendation - MSN
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat
Cytokinetics Executive Sells 15,000 Shares - TradingView — Track All Markets
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.
Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat
Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech
Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech
Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Stock Soars: What’s Next? - StocksToTrade
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech
Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
What Does the Market Think About Cytokinetics Inc? - Benzinga
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Cytokinetics FY2025 EPS Forecast Reduced by HC Wainwright - MarketBeat
Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Insider Sell: Wendell Wierenga Sells 20,000 Shares of Cytokineti - GuruFocus
Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing - marketscreener.com
Morgan Stanley Maintains Overweight Rating on CYTK, Raises PT to $71 | CYTK Stock News - GuruFocus
4.73%
0.92%
자본화:
|
볼륨(24시간):